Rexall and Novo Nordisk Canada launch nationwide home delivery for Ozempic, Wegovy and Rybelsus

Rexall and Novo Nordisk Canada began offering home delivery of Ozempic, Wegovy and Rybelsus through a new program called Novo Nordisk Care Rx on August 21, 2026 ^[1]. The service covers every province and territory except Quebec, which has its own drug-distribution rules that keep it outside the program ^[1].

The launch comes as Canada's generic semaglutide market takes shape. Health Canada has approved 3 of 9 generic semaglutide products under review, with Dr. Reddy's authorized on April 28 and Apotex now offering full SKU parity with brand-name Ozempic ^[1]. The BMJ has reported that Canada is only the second country in the world to approve a generic semaglutide product ^[1]. Seven more generic semaglutide submissions were still awaiting a decision as of early August, part of a broader Health Canada backlog that industry groups say tops 500 generic drug files ^[1].

Pricing in Canada is set to shift as more generics enter the market. Under the country's pCPA framework, a first generic semaglutide is priced at 75 to 85 percent of the brand-name cost, and that price is set to fall to 35 percent of brand once three or more generic versions are available ^[1]. Plan sponsors have been told to expect a 65 percent cut in the list price once a third generic launches, with Sandoz reportedly targeting a Q3 2026 entry ^[1]. Days before the Rexall delivery launch, Novo Nordisk introduced a separate savings card for uninsured Canadians buying Ozempic, aligning its brand price with generic pricing; that card also runs through Rexall pharmacies and also excludes Quebec ^[1].

Novo Nordisk has told investors to expect a 5 to 13 percent drop in 2026 sales as Canadian generics reach pharmacies ^[1]. Patent tracking group I-MAK has said Novo Nordisk could have extended its Canadian Ozempic patent to 2028 but did not renew it, after the company stopped paying an annual patent maintenance fee of about C$250 in 2018 ^[1].

Why it matters for patients

For patients who already fill Ozempic, Wegovy or Rybelsus at Rexall outside Quebec, home delivery adds a new way to get refills without a pharmacy visit ^[1]. It does not change the price of the brand-name drug on its own, but it arrives alongside Novo Nordisk's separate savings card for uninsured patients, which is meant to bring brand pricing closer to what generic semaglutide costs ^[1].

Patients weighing brand versus generic semaglutide should know the generic market in Canada is still forming. Only a fraction of submitted generic products have been approved so far, and the price gap between brand and generic is expected to widen as more generics launch, per the pCPA's tiered pricing rules ^[1]. Health Canada has also warned about counterfeit and unauthorized GLP-1 products being sold outside licensed pharmacies, a risk that grows as demand and price sensitivity increase ^[1]. Patients in Quebec cannot use either the new home-delivery service or the savings card because of the province's separate drug-distribution rules ^[1].

What happens next

Health Canada is still reviewing seven generic semaglutide files as of early August 2026 ^[1]. Sandoz has said it is targeting a Q3 2026 launch for its own generic semaglutide, a milestone that would trigger the deeper 65 percent list-price cut plan sponsors have been told to expect ^[1]. Novo Nordisk's full 2026 financial results, expected later in the year, will show whether the 5 to 13 percent sales decline it has forecast for Canada materializes as generic competition expands ^[1].